Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn’s Disease: A Canadian Multi-Centre Observational Cohort Study

BACKGROUND: Ustekinumab (UST), an anti-IL12/23 inhibitor is indicated for moderate-to-severe Crohn’s disease (CD). However, it is unclear if patients treated with UST are at increased risk for postoperative complications. AIM: To evaluate the postoperative safety outcomes in UST-treated CD patients....

Descripción completa

Detalles Bibliográficos
Autores principales: Shim, Hang Hock, Ma, Christopher, Kotze, Paulo G, Seow, Cynthia H, Al-Farhan, Heba, Al-Darmaki, Ahmed K, Pang, Jack X Q, Fedorak, Richard N, Devlin, Shane M, Dieleman, Levinus A, Kaplan, Gilaad G, Novak, Kerri L, Kroeker, Karen I, Halloran, Brendan P, Panaccione, Remo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507292/
https://www.ncbi.nlm.nih.gov/pubmed/31294352
http://dx.doi.org/10.1093/jcag/gwy013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507292/
https://www.ncbi.nlm.nih.gov/pubmed/31294352
http://dx.doi.org/10.1093/jcag/gwy013

Ejemplares similares